Overview

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Other find tumor cells and help kill them or carry tumor-killing substances to them. Giving panitumumab together with paclitaxel and carboplatin may be a better way to block tumor growth. PURPOSE: This phase II trial is studying the side effects and how well paclitaxel and carboplatin together with panitumumab works in treating patients with metastatic triple negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Paclitaxel
Panitumumab